Oncology: Frequently Asked Questions

Oncology is the branch of medicine devoted to the diagnosis, treatment, and long-term management of cancer — a group of diseases that, combined, affect approximately 1.9 million Americans per year according to the National Cancer Institute's SEER Program. The questions below address how oncology works as a clinical discipline, what patients and families can expect from the diagnostic and treatment process, and where authoritative guidance is maintained. Coverage spans foundational concepts through jurisdiction-specific regulatory considerations, with references to named public agencies and published standards throughout.

What should someone know before engaging?

Oncology operates within a heavily regulated clinical environment governed by agencies including the U.S. Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), and the National Comprehensive Cancer Network (NCCN), which publishes evidence-based clinical practice guidelines across more than 97 cancer types. A diagnosis does not automatically determine a treatment pathway — staging, molecular profiling, and performance status each independently shape clinical decisions.

Patients navigating an initial cancer diagnosis should understand that oncology itself is not a single specialty. Medical oncology, radiation oncology, and surgical oncology represent three distinct training tracks and scope-of-practice domains. Multidisciplinary tumor boards — formal panels at major cancer centers that typically include representatives from all three disciplines plus pathology and radiology — review complex cases before treatment recommendations are finalized. The American College of Surgeons Commission on Cancer (CoC) accredits cancer programs in part based on the functioning of these boards.

For an orientation to the field's foundational concepts, the oncology overview at /index provides structured entry points across diagnosis, treatment, and survivorship topics.

What does this actually cover?

The clinical scope of oncology encompasses the full continuum from cancer risk assessment through end-of-life care. Diagnostic oncology includes imaging, biopsy procedures, laboratory analysis, and molecular profiling of tumor biomarkers. Treatment oncology spans systemic therapies — chemotherapy, immunotherapy, targeted therapy, and hormone therapy — alongside radiation therapy, surgical oncology, and advanced interventions such as CAR-T cell therapy and bone marrow or stem cell transplantation.

Post-treatment oncology covers follow-up surveillance, cancer survivorship programs, palliative care, and management of long-term treatment effects. Preventive oncology addresses genetic counseling for hereditary risk, population-level cancer screening guidelines, and chemoprevention where applicable.

What are the most common issues encountered?

Delayed diagnosis remains a persistent clinical and public health challenge. The American Cancer Society reports that colorectal cancer, lung cancer, and ovarian cancer are frequently identified at advanced stages in part because early-stage symptoms overlap with benign conditions and because screening uptake remains below recommended targets in eligible populations.

Insurance coverage disputes represent a second common operational issue. Certain treatments — including clinical trials, off-label drug use, and genomic sequencing panels — face inconsistent coverage determinations across payers, a gap that CMS has addressed incrementally through Coverage with Evidence Development (CED) pathways. Financial considerations specific to cancer treatment are a documented source of treatment delay and non-adherence.

Side effect burden is a third recurring issue. Nausea, fatigue, neuropathy, and immunosuppression vary substantially by treatment modality and patient-specific factors. Managing side effects is a formal component of oncologic care, not an adjunct to it.

How does classification work in practice?

Cancer classification operates across four primary axes:

  1. Anatomic site — where the tumor originates (e.g., breast cancer, prostate cancer, thyroid cancer)
  2. Histologic type — the cell type involved (carcinoma, sarcoma, leukemia, lymphoma, melanoma, and others)
  3. Stage — the extent of disease spread, most commonly using the TNM system (Tumor, Node, Metastasis) maintained by the American Joint Committee on Cancer (AJCC) in its Cancer Staging Manual, currently in its 8th edition
  4. Molecular/genomic profile — mutations, receptor expression, and biomarkers that determine targeted therapy eligibility

Benign versus malignant tumor classification precedes all staging. A tumor confirmed as malignant on pathology report then undergoes cancer staging and grading, which drives treatment intensity and prognosis estimates. Grading (G1 through G4) reflects cellular differentiation independent of anatomic spread.

What is typically involved in the process?

A standard oncology care sequence moves through discrete phases:

  1. Initial evaluation — symptom review, physical examination, review of abnormal screening results or warning signs
  2. Diagnostic workup — imaging, blood tests and tumor markers, genetic testing for cancer risk, and tissue biopsy
  3. Pathologic confirmation — histologic and molecular analysis producing a formal pathology report
  4. Staging and multidisciplinary review — tumor board presentation, performance status assessment
  5. Treatment planning — selection of modality or combination therapy approach
  6. Active treatment — delivery of systemic, radiation, or surgical therapy per protocol
  7. Response assessment — interval imaging and laboratory reassessment
  8. Post-treatment care — surveillance scheduling, survivorship planning, emotional health support

Each phase may involve a second opinion, which major oncology centers including those accredited by the National Cancer Institute (NCI) as Comprehensive Cancer Centers actively accommodate.

What are the most common misconceptions?

Misconception 1: A cancer diagnosis means treatment begins immediately. In most cases, a period of 1–3 weeks for complete workup and treatment planning does not worsen outcomes and enables more precise therapy selection.

Misconception 2: Surgery is always the primary treatment. For hematologic malignancies such as leukemia and lymphoma, surgery plays no primary therapeutic role. For skin cancer subtypes including basal cell carcinoma, surgery is first-line; for others, radiation or topical therapy is preferred.

Misconception 3: Clinical trials are a last resort. The NCI defines clinical trials as a standard option at any stage of treatment, including first-line therapy, and Phase III trials often compare experimental agents directly against established standard-of-care regimens.

Misconception 4: Oncologists and hematologists are entirely separate specialties. Hematology-oncology is a combined fellowship recognized by the American Board of Internal Medicine (ABIM), and physicians completing hematology-oncology fellowship training are board-certified to manage both blood disorders and solid tumor malignancies.

Where can authoritative references be found?

The following named public and professional sources maintain evidence-based oncology information:

For questions about the regulatory context governing oncology practice in the United States, NCI, FDA, and CMS are the three primary federal agencies with overlapping jurisdiction.

How do requirements vary by jurisdiction or context?

Oncology care requirements vary across three primary dimensions:

Federal vs. State Licensing: Oncologists hold medical licenses issued by individual state medical boards, meaning a physician licensed in one state cannot practice in another without separate licensure — unless operating under telehealth interstate compact arrangements. The Interstate Medical Licensure Compact (IMLC) facilitates expedited licensure across 39 participating states and territories as of its most recent published roster.

Facility Accreditation: Cancer programs seeking CoC accreditation from the American College of Surgeons must meet standards around tumor registry reporting, multidisciplinary care, and quality benchmarks. Non-accredited facilities are not prohibited from delivering oncology care, but CoC accreditation is often used by insurers as a quality indicator.

Drug Approval Status: FDA approval determines whether a therapy can be commercially marketed for a specific indication. Off-label use — prescribing an approved drug for an unapproved indication — is legally permitted in clinical practice but may affect insurance reimbursement. Accelerated approval pathways, used for 64 oncology indications between 1992 and 2023 according to FDA records, attach post-marketing confirmatory trial requirements.

Pediatric vs. Adult Oncology: Pediatric oncology operates under distinct regulatory frameworks. The Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies for certain new drug applications, and the Children's Oncology Group (COG) coordinates the majority of pediatric cancer clinical trials in North America across more than 200 member institutions. Safety context and risk stratification in oncology differ materially between pediatric and adult populations in both toxicity tolerance and long-term survivorship considerations.

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)